Your browser doesn't support javascript.
loading
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
Corbett, Kizzmekia S; Werner, Anne P; Connell, Sarah O'; Gagne, Matthew; Lai, Lilin; Moliva, Juan I; Flynn, Barbara; Choi, Angela; Koch, Matthew; Foulds, Kathryn E; Andrew, Shayne F; Flebbe, Dillon R; Lamb, Evan; Nurmukhambetova, Saule T; Provost, Samantha J; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; Ry, Alex Van; Flinchbaugh, Zackery; Johnston, Timothy S; Mokhtari, Elham Bayat; Mudvari, Prakriti; Henry, Amy R; Laboune, Farida; Chang, Becky; Porto, Maciel; Wear, Jaclyn; Alvarado, Gabriela S; Boyoglu-Barnum, Seyhan; Todd, John-Paul M; Bart, Bridget; Cook, Anthony; Dodson, Alan; Pessaint, Laurent; Steingrebe, Katelyn; Elbashir, Sayda; Sriparna, Manjari; Pekosz, Andrew; Andersen, Hanne; Wu, Kai; Edwards, Darin K; Kar, Swagata; Lewis, Mark G; Boritz, Eli; Moore, Ian N; Carfi, Andrea; Suthar, Mehul S; McDermott, Adrian; Roederer, Mario.
Afiliação
  • Corbett KS; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Werner AP; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Connell SO; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Gagne M; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lai L; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Moliva JI; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Flynn B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Choi A; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Koch M; Moderna, Cambridge, MA, USA.
  • Foulds KE; Moderna, Cambridge, MA, USA.
  • Andrew SF; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flebbe DR; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Lamb E; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nurmukhambetova ST; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Provost SJ; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Bock KW; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Minai M; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nagata BM; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ry AV; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flinchbaugh Z; Bioqual, Rockville, MD, USA.
  • Johnston TS; Bioqual, Rockville, MD, USA.
  • Mokhtari EB; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mudvari P; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Henry AR; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Laboune F; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Chang B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Porto M; Bioqual, Rockville, MD, USA.
  • Wear J; Bioqual, Rockville, MD, USA.
  • Alvarado GS; Bioqual, Rockville, MD, USA.
  • Boyoglu-Barnum S; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Todd JM; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Bart B; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Cook A; Bioqual, Rockville, MD, USA.
  • Dodson A; Bioqual, Rockville, MD, USA.
  • Pessaint L; Bioqual, Rockville, MD, USA.
  • Steingrebe K; Bioqual, Rockville, MD, USA.
  • Elbashir S; Bioqual, Rockville, MD, USA.
  • Sriparna M; Moderna, Cambridge, MA, USA.
  • Pekosz A; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Andersen H; Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
  • Wu K; Bioqual, Rockville, MD, USA.
  • Edwards DK; Moderna, Cambridge, MA, USA.
  • Kar S; Moderna, Cambridge, MA, USA.
  • Lewis MG; Bioqual, Rockville, MD, USA.
  • Boritz E; Bioqual, Rockville, MD, USA.
  • Moore IN; Vaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Carfi A; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Suthar MS; Moderna, Cambridge, MA, USA.
  • McDermott A; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
  • Roederer M; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
Nat Immunol ; 22(10): 1306-1315, 2021 10.
Article em En | MEDLINE | ID: mdl-34417590
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna's mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log10 reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log10 reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Primatas / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Primatas / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos